ProShare Advisors
AUTL

ProShare Advisors’s Autolus Therapeutics AUTL Stock Holding History

ProShare Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,796
Closed -$42.8K – 2274
2024
Q3 		$42.8K Sell
11,796
-517
-4% -$2.06K ﹤0.01% 1992
2024
Q2 		$42.8K Buy
+12,313
New +$53.1K ﹤0.01% 1762
2021
Q4 		– Sell
-12,192
Closed -$80K – 2339
2021
Q3 		$80K Buy
+12,192
New +$77K ﹤0.01% 1935
2019
Q1 		– Sell
-6,121
Closed -$201K – 1659
2018
Q4 		$201K Buy
+6,121
New +$201K ﹤0.01% 1373

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

ProShare Advisors's AUTL Position: Q4 2024 in Review

ProShare Advisors sold out of Autolus Therapeutics (AUTL) in Q4 2024, closing a stake of 11,796 shares — an estimated $42.8K sold.

ProShare Advisors first reported a position in AUTL in Q4 2018 and held it in 4 quarters. The position peaked at $201K in Q4 2018. 110 funds tracked by Wall St. Rank hold AUTL as of Q4 2024.

  • ProShare Advisors reported no remaining Autolus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • ProShare Advisors sold 11,796 Autolus Therapeutics shares in Q4 2024, an estimated $42.8K.
  • ProShare Advisors first reported a position in Autolus Therapeutics in Q4 2018 and held it in 4 quarters.
  • ProShare Advisors's Autolus Therapeutics position peaked at $201K in Q4 2018.
  • 110 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2024.

Based on ProShare Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.